title: [Prostate adenocarcinoma. Predictive clinical model of seminal vesicle involvement].
abstract: OBJECTIVE
  Our aim is to design a predictive model of seminal vesicle involvement. using clinical data.
  
  
  METHODS
  We studied 1128 patients with clinically localized adenocarcinoma treated by radical prostatectomy (127 were pT3b). We identified (logistic regression) clinical variables related with pT3b. With the multivariate study influential variables a seminal vesicle involvement risk model is designed.
  
  
  RESULTS
  Seminal vesicle involvement related factors: In univariate study: the influential variables are: Gleason 7 (OR:2);Gleason 8-10 (OR:4.5) T2 (OR:2.6); bilateral involvement in biopsy (OR:3.1); PSA 10-20 ng/ml ( OR:3.3); PSA >20 ng/ ml (OR:9.5). In the multivariate study are influential: Gleason 7 (OR:1.56) Gleason 8-10 ( OR: 3.4); T2 (OR:1.9); PSA 10-20 ng/ml (OR:3.1) and PSA >20 ng/,ml (OR:8.8). Predictive model: using multivariate logistic regression the weight of each variable is valued and a value between 1 and 4 is given. Gleason 2-6, T1; PSA<10 ng/ml value 1; Gleason 7; T2 y PSA 10-20 ng/ml value 2; Gleason 8-10 and PSA >20 ng/ml value 4. Each patient has a marker that fluctuates between 3 and 10. 5 Groups are designed with significantly different risks (p<0.05 in all cases ): Group 1 (3 points) (OR:1) (risk: 2.4% 95%IC 0.7%-4.3%) Group 2 (4 points) (OR:2.7) (risk: 6.5% 95%IC 5%-7.9%); Group 3(5-6 points) (OR:7.1)( risk:15% 95%IC 11%-19%) Group 4 ( 7--8 points) (OR:33.4) (risk: 45.5%; 95%IC 30%-59%) Group 5 (9-10 points) (OR:57.3) (risk: 58.8% 95%IC 35%- 82%).
  
  
  CONCLUSIONS
  The clinical model allows an accurate approximation to the seminal vesicles involvement risk.
authors.affiliation: Departamento de Urología. Clínica Universidad de Navarra. Navarra. España.
authors.forename: Rubén
authors.initials: R
authors.lastname: Algarra
authors.forename: Jose María
authors.initials: JM
authors.lastname: Velis
authors.forename: Antonio
authors.initials: A
authors.lastname: Tienza
authors.forename: Imanol
authors.initials: I
authors.lastname: Merino
authors.forename: Javier
authors.initials: J
authors.lastname: Barba
authors.forename: Egoitz
authors.initials: E
authors.lastname: Tolosa
authors.forename: Anibal
authors.initials: A
authors.lastname: Rincón
authors.forename: Jorge
authors.initials: J
authors.lastname: Rioja
authors.forename: Javier
authors.initials: J
authors.lastname: Zudaire
authors.forename: Ignacio
authors.initials: I
authors.lastname: Pascual
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology* / Q000601:surgery; D000328:Adult; D018450:Disease Progression; D006801:Humans; D008297:Male; D011237:Predictive Value of Tests; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000601:surgery; D018570:Risk Assessment; D012669:Seminal Vesicles / Q000473:pathology*